Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.51 |
| ▸ | KRAS | P01116 | 4/20 | 0.49 |
| ▸ | ELANE | P08246 | 4/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | EHD1 | Q9H4M9 | 4/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGAV | P06756 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29414461 | 0.97 | KRAS (0.49) | PLGKRASELANEHDAC4HDAC3 | |
| SCHEMBL29773723 | 0.97 | KRAS (0.49) | PLGKRASELANEHDAC4HDAC3 | |
| SCHEMBL29773725 | 0.97 | KRAS (0.49) | PLGKRASELANEHDAC4HDAC3 | |
| SCHEMBL29773694 | 0.97 | KRAS (0.49) | PLGKRASELANEHDAC4HDAC3 | |
| SCHEMBL29886188 | 0.97 | KRAS (0.49) | PLGKRASELANEHDAC4HDAC3 | |
| SCHEMBL29884632 | 0.95 | KRAS (0.51) | PLGKRASELANEHDAC4HDAC3 | |
| SCHEMBL31612918 | 0.95 | KRAS (0.51) | PLGKRASELANEHDAC4HDAC3 | |
| SCHEMBL19214159 | 0.95 | KRAS (0.48) | PLGKRASELANEHDAC4HDAC3 | |
| SCHEMBL29773756 | 0.93 | PLG (0.51) | PLGKRASELANEHDAC4HDAC3 | |
| SCHEMBL24756492 | 0.93 | KRAS (0.49) | PLGKRASELANEHDAC4HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3755357-B1 | AN ANTIBIOTIC COMPOSITION COMPRISING MICELLES | SPOREGEN LTD (GB) | 2025-09-17 | — | — | EP | claimed |
| US-12171734-B2 | Pathogenic bacteria | SPOREGEN LIMITED (GB) | 2024-12-24 | — | — | US | claimed |
| US-20230136991-A1 | ITURIN FAMILY LIPOPEPTIDES IN PEST CONTROL | INSTITUTE OF BIOLOGY, HEBEI ACADEMY OF SCIENCES (CN) | 2023-05-04 | — | — | US | claimed |
| WO-2022228058-A1 | APPLICATION OF ITURIN FAMILY LIPOPEPTIDES IN PEST CONTROL | 河北省科学院生物研究所 | 2022-11-03 | — | — | WO | claimed |
| US-20250295748-A1 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS | SPOREGEN LIMITED (GB) | 2025-09-25 | — | — | US | disclosed |
| EP-3755357-B1 | AN ANTIBIOTIC COMPOSITION COMPRISING MICELLES | SPOREGEN LTD (GB) | 2025-09-17 | — | — | EP | disclosed |
| US-20250270567-A1 | GENERATION OF ACYL AMINO ACIDS | MODULAR GENETICS INC (US) | 2025-08-28 | — | — | US | disclosed |
| WO-2025084927-A1 | MYCOSUBTILIN IN BAKERY PRODUCTS | MAURI TECHNOLOGY B.V. (NL) | 2025-04-24 | — | — | WO | disclosed |
| US-20250127176-A1 | BIO-FUNGICIDES FORMULATIONS FOR INHIBITING PHYTOPHTHORA INFESTANS AND METHOD THEREOF | TAMIL NADU AGRICULTURAL UNIVERSITY (IN) | 2025-04-24 | — | — | US | disclosed |
| US-12171734-B2 | Pathogenic bacteria | SPOREGEN LIMITED (GB) | 2024-12-24 | — | — | US | disclosed |
| US-12123004-B2 | Generation of acyl amino acids | MODULAR GENETICS, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| EP-4408975-A1 | BIO-FUNGICIDES FORMULATIONS FOR INHIBITING PHYTOPHTHORA INFESTANS AND METHOD THEREOF | Coromandel International Limited (IN) | 2024-08-07 | — | — | EP | disclosed |
| CN-108347940-B | Microbial pesticide compositions and preparation thereof | 科.汉森有限公司 | 2022-10-14 | — | — | CN | disclosed |
| WO-2022215495-A1 | METHOD FOR REDUCING BIOBURDEN OF CYCLIC LIPOPEPTIDE COMPOUND | 株式会社カネカ | 2022-10-13 | — | — | WO | disclosed |
| US-20220280579-A1 | Formulations for Prevention or Reduction of C. Difficile Infections | SPOREGEN LIMITED (GB) | 2022-09-08 | — | — | US | disclosed |
| US-20220259626-A1 | GENERATION OF ACYL AMINO ACIDS | MODULAR GENETICS, INC. | 2022-08-18 | — | — | US | disclosed |
| EP-4017265-A1 | FORMULATIONS FOR PREVENTION OR REDUCTION OF C. DIFFICILE INFECTIONS | SporeGen Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| WO-2022049381-A1 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS | SPOREGEN LIMITED (GB) | 2022-03-10 | — | — | WO | disclosed |
| WO-2022040271-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING FUNGAL DISEASES IN PLANTS | BAYER CROPSCIENCE LP (US) | 2022-02-24 | — | — | WO | disclosed |
| CN-113115777-B | Application of iturin family lipopeptide in pest control | 河北省科学院生物研究所 | 2022-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280579-A1 | Formulations for Prevention or Reduction of C. Difficile Infections | SI, FABP2, CRY1 | PLG 2274/4885KRAS 4197/4885ELANE 500/4885 |
| US-12171734-B2 | Pathogenic bacteria | CLPP, CLPX, ANTXR2 | PLG 2209/4885KRAS 3299/4885ELANE 725/4885 |
| US-20220259626-A1 | GENERATION OF ACYL AMINO ACIDS | FADS1, FADS2, FAR1 | PLG 1385/4885KRAS 973/4885ELANE 1073/4885 |
| US-20250295748-A1 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS | TLR3, TLR5, IRF3 | PLG 4714/4885KRAS 2371/4885ELANE 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.